Fate Therapeutics Stock News

Fate Therapeutics Inc (FATE) shares closed 3.2% lower than its previous 52 week low, giving the company a market cap of $4B. The stock is currently down 23.0% year-to-date, down 59.8% over the past 12 months, and up 1532.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 23.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 134.1% The company's stock price performance over the past 12 months lags the peer average by 143.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

Fate Therapeutics, Inc. (NASDAQ:FATE) CFO Edward J. Dulac III sold 15,977 shares of Fate Therapeutics stock in a transaction that occurred on Monday, December 20th. The stock was sold at an average price of $60.00, for a total value of $958,620.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, []

Tygh Capital Management Inc. lifted its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) by 33.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 48,773 shares of the biopharmaceutical companys stock after purchasing an additional 12,358 shares during the quarter. Tygh Capital Management Inc. owned about 0.05% of []

Related Stocks: FATE ,

Fate Therapeutics, Inc. (NASDAQ:FATE)s stock price traded up 6.2% during trading on Friday . The company traded as high as $55.13 and last traded at $54.85. 56,216 shares were traded during mid-day trading, a decline of 95% from the average session volume of 1,027,269 shares. The stock had previously closed at $51.63. FATE has been []

Emerald Mutual Fund Advisers Trust purchased a new position in Fate Therapeutics, Inc. (NASDAQ:FATE) during the third quarter, HoldingsChannel.com reports. The fund purchased 80,289 shares of the biopharmaceutical companys stock, valued at approximately $4,759,000. Several other institutional investors have also bought and sold shares of the company. Bridgefront Capital LLC lifted its position in shares []

Fate Therapeutics (NASDAQ:FATE) had its target price raised by HC Wainwright from $121.00 to $122.00 in a research report released on Wednesday, Price Targets.com reports. They currently have a buy rating on the biopharmaceutical companys stock. Other analysts have also issued reports about the stock. Citigroup upgraded shares of Fate Therapeutics from a neutral rating []

Fate Therapeutics, Inc. (NASDAQ:FATE) gapped up before the market opened on Wednesday after HC Wainwright raised their price target on the stock from $121.00 to $122.00. The stock had previously closed at $50.17, but opened at $51.86. HC Wainwright currently has a buy rating on the stock. Fate Therapeutics shares last traded at $50.28, with []

The stock price of Fate Therapeutics, Inc. (NASDAQ: FATE) increased by 2.43% today. This is why it happened.

Fate Therapeutics Inc (NASDAQ: FATE ) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the American Society of Hematology (ASH) Annual Meeting and Exposition. In the second, third, and fourth dose cohorts of monotherapy and combination arms comprising 26 patients, 18 patients (69%) achieved an objective response, including 12 patients (46%) that achieved a complete response, on Day 29 following a single dose of FT596. 5 of Full story available on Benzinga.com

Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the American Society of Hematology (ASH)

5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab

6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose

SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event entitled B -cell Lymphoma Franchise Update on Tuesday, December 14, 2021 at 8:00 AM ET.